Entropy Technologies’s Myriad Genetics MYGN Stock Holding History

Entropy Technologies’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,300	Closed	-$87.9K	–	1067
2025 Q4	$87.9K	Buy	+14,300	New	+$104K	﹤0.01%	846
2025 Q1	–	Sell	-12,998	Closed	-$178K	–	891
2024 Q4	$178K	Buy	+12,998	New	+$240K	0.02%	648

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Entropy Technologies's MYGN Position: Q1 2026 in Review

Entropy Technologies sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 14,300 shares — an estimated $87.9K sold.

Entropy Technologies first reported a position in MYGN in Q4 2024 and held it in 2 quarters. The position peaked at $178K in Q4 2024. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Entropy Technologies reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Entropy Technologies sold 14,300 Myriad Genetics shares in Q1 2026, an estimated $87.9K.
Entropy Technologies first reported a position in Myriad Genetics in Q4 2024 and held it in 2 quarters.
Entropy Technologies's Myriad Genetics position peaked at $178K in Q4 2024.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.